本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码： 600682 证券简称：南京新百 公告编号：临2023-038 南京新街口百货商店股份有限公司 关于董事辞职及补选董事的公告 袁千惠女士未持有公司股份，未受到中国证监会及其他有关部门的处罚和证 券交易所惩戒，其非独立董事候选人的任职资格符合《公司法》、《公司章程》 的规定。简历详见附件。 该议案尚需提交至公司股东大会审议。 特此公告。 南京新街口百货商店股份有限公司 董事会 2023年12月16日 1 南京新街口百货商店股份有限公司(以下简称公司或本公司)董事会于近日收 到公司董事张雷先生递交的辞职报告，张雷先生因公司工作调整原因，向公司辞 去公司董事职务。 根据《公司法》、《上海证券交易所股票上市规则》以及《公司章程》有关规定， 辞职申请以送达董事会之日起生效。张雷先生辞职不会导致公司董事会成员人数低 于法定要求，不会影响公司及董事会的正常运作。 张雷先生在担任公司董事期间勤勉尽责，公司及董事会对张雷先生在任职期间 为公司发展所做的贡献表示衷心感谢。 根据《公司法》 ...

证券代码：600682 证券简称：南京新百 公告编号：临 2023-036 南京新街口百货商店股份有限公司 关于股东部分股份解除质押及质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司股东银丰生物工程集团有限公司（以下简称银丰生物）持有南京新 街口百货商店股份有限公司（以下简称公司）股份数量为 96,722,192 股，占公 司总股本的 7.19%。本次股份解除质押及质押后，银丰生物累计质押数量为 61,184,164 股（含本次），占其持有公司股份数的 63.26%，占公司总股本的 4.55%， 剩余未质押股份数量为 35,538,028 股。 证券代码：600682 证券简称：南京新百 公告编号：临 2023-036 公司近日收到股东银丰生物关于其所持公司股份解除质押及质押登记的说 明，现将有关情况公告如下： | 股东名称 | 银丰生物工程集团有限公司 | | | | | | --- | --- | --- | --- | --- | --- | | 本次解质股份 | | | 32,357,2 ...

Revenue and Costs - Total operating revenue for the first three quarters of 2023 reached 4,756,623,138.17 yuan, compared to 4,663,340,447.80 yuan in the same period of 2022[13] - Total operating costs for the first three quarters of 2023 were 4,117,070,060.96 yuan, up from 3,802,240,866.18 yuan in the same period of 2022[13] - Revenue for the reporting period was 1,518,623,752.32 yuan, a decrease of 7.87% year-over-year[31] Assets and Liabilities - The company's total assets as of September 30, 2023, amounted to 25,840,412,408.24 yuan, compared to 25,215,359,602.91 yuan at the end of 2022[13] - Total liabilities as of September 30, 2023, were 7,002,517,134.24 yuan, slightly down from 7,042,748,127.18 yuan at the end of 2022[13] - Shareholders' equity increased to 18,837,895,274.00 yuan as of September 30, 2023, from 18,172,611,475.73 yuan at the end of 2022[13] - Total assets at the end of the reporting period were 25,840,412,408.24 yuan, an increase of 2.48% compared to the end of the previous year[31] - Total assets increased to 25,840,412,408.24 from 25,215,359,602.91[46] Cash Flow - Cash received from sales of goods and services was 6,164,623,872.53 RMB, slightly down from 6,202,219,632.53 RMB in the same period last year[23] - Cash paid for goods and services was 2,675,031,475.65 RMB, up from 2,544,170,156.61 RMB in the same period last year[23] - Cash paid to and for employees was 2,045,450,039.75 RMB, up from 1,884,610,341.70 RMB in the same period last year[23] - Total operating cash inflow was 6,603,735,229.30 RMB, slightly down from 6,644,652,967.26 RMB in the same period last year[23] - Total operating cash outflow was 6,045,258,617.07 RMB, up from 5,690,958,819.24 RMB in the same period last year[23] - Net cash flow from operating activities was 558,476,612.23 yuan, a decrease of 41.44% year-over-year[31] - Net cash flow from investing activities was -948,160,870.39 yuan, compared to -2,829,955,455.50 yuan in the same period last year[33] - Net cash flow from financing activities was 55,455,882.87 yuan, compared to -292,207,886.55 yuan in the same period last year[33] - Cash and cash equivalents at the end of the period were 4,591,462,944.89 yuan, a decrease from 4,872,456,964.62 yuan at the beginning of the period[33] Profit and Loss - Net profit attributable to parent company shareholders was 397,843,076.60 RMB, compared to 613,997,506.71 RMB in the same period last year[20] - Total comprehensive income for the period was 690,450,986.38 RMB, compared to 1,508,277,551.61 RMB in the same period last year[20] - Basic earnings per share were 0.30 RMB, compared to 0.46 RMB in the same period last year[23] - Net profit attributable to shareholders of the listed company was 76,110,777.25 yuan, a decrease of 65.06% year-over-year[31] - Net profit attributable to shareholders decreased by 65.06% in the current reporting period due to a decline in main business performance[39] - Net profit attributable to shareholders decreased by 35.20% from the beginning of the year to the reporting period due to a decline in main business performance[39] Expenses - R&D expenses were 200,084,818.54 RMB, up from 190,707,290.78 RMB in the same period last year[17] - Sales expenses were 416,552,910.93 RMB, down from 433,779,506.79 RMB in the same period last year[17] - Financial expenses decreased by 616.52% from the beginning of the year to the reporting period due to increased interest income[39] Inventory and Development - Inventory increased significantly to 470,660,482.11 yuan as of September 30, 2023, from 287,490,302.87 yuan at the end of 2022[11] - Development expenditure increased by 104.42% at the end of the reporting period due to the advancement of R&D projects[39] - Inventory increased by 63.71% at the end of the reporting period due to an increase in raw materials[39] Other Financial Metrics - The company's monetary funds decreased to 4,630,121,536.44 yuan as of September 30, 2023, from 4,934,614,531.76 yuan at the end of 2022[11] - Trade receivables slightly decreased to 1,195,214,918.13 yuan as of September 30, 2023, from 1,196,131,960.44 yuan at the end of 2022[11] - Fixed assets increased to 3,485,393,712.06 yuan as of September 30, 2023, from 2,999,939,557.56 yuan at the end of 2022[11] - Non-recurring gains and losses amounted to 7,463,478.51 yuan for the reporting period[38] - Government subsidies included in current profits were 1,134,781.13 yuan[38] - Fair value changes from financial assets and liabilities amounted to 9,852,734.34 yuan[38] - Other comprehensive income decreased by 61.09% at the end of the reporting period due to exchange rate fluctuations[39] - Credit impairment losses increased by 36.96% from the beginning of the year to the reporting period due to increased provisions[39] - Contract liabilities increased to 3,234,679,542.05 from 3,057,122,549.54[46] Shareholders - The company's total number of ordinary shareholders at the end of the reporting period was 38,388[5]

Financial Performance - The company's operating revenue for the first half of 2023 was approximately RMB 3.24 billion, representing a 7.40% increase compared to RMB 3.01 billion in the same period last year[12]. - The net profit attributable to shareholders of the listed company decreased by 18.79% to approximately RMB 321.73 million, down from RMB 396.15 million in the previous year[12]. - The net cash flow from operating activities was approximately RMB 414.22 million, a decline of 39.07% compared to RMB 679.78 million in the same period last year[12]. - Basic earnings per share for the first half of 2023 were CNY 0.24, a decrease of 17.24% compared to the same period last year[37]. - The weighted average return on equity for the first half of 2023 was 1.86%, down from 2.26% in the previous year[37]. - The company achieved operating revenue of 3.238 billion yuan, with a net profit attributable to shareholders decreasing by 74 million yuan, a decline of 18.79% year-on-year[84]. Assets and Liabilities - The net assets attributable to shareholders of the listed company increased by 3.42% to approximately RMB 17.54 billion, compared to RMB 16.96 billion at the end of the previous year[12]. - Total assets rose by 2.79% to approximately RMB 25.92 billion, up from RMB 25.22 billion at the end of the previous year[12]. - The total assets at the end of the reporting period amounted to ¥25,919,000,000, with cash and cash equivalents accounting for 19.91% of total assets[119]. - The company’s inventory increased by 67.02% to ¥480,164,250.64, primarily due to an increase in raw materials[119]. - The company’s contract liabilities rose by 4.23% to ¥3,186,585,920.84, indicating growth in prepayments received[119]. - The company reported a loan balance of 310 million yuan as of June 30, 2023, secured by the outpatient building and corresponding land use rights of its subsidiary, Xuzhou New Health Geriatric Hospital Co., Ltd.[182]. Business Operations - The company operates primarily in the department store retail sector, with a business model that includes joint ventures and leasing[28]. - The company continues to enhance the synergy between its nursing business and private pay services, with a total of 4.5 million hours of nursing services provided during the reporting period[14]. - Ankangtong's revenue in the first half of 2023 showed a year-on-year growth, with home care services remaining the primary business segment, while long-term care insurance's share increased[34]. - The company has successfully won over 200 projects, including home care services in Xiangcheng and Tonglu, and has expanded into new provinces such as Liaoning and Anhui in the first half of 2023[34]. - The company has established over 100 smart elderly care command centers across various regions, enhancing its operational capabilities[34]. - The company is focusing on expanding its business areas while maintaining existing operations in home and community elderly care[56]. Market and Competition - The company faces operational risks due to macroeconomic downturns and market competition, which investors should be aware of[15]. - The company faces market competition risks in the healthcare sector, with increasing competition from state-owned enterprises and industry leaders entering the market[169]. - The company is facing intensified competition in the mCRPC treatment market, with multiple competing products available[175]. - The company is monitoring the impact of declining birth rates on its core business, which relies on newborn delivery volumes[170]. Strategic Initiatives - The company aims to integrate technology with traditional elderly care services, enhancing its service delivery through innovative solutions[30]. - The company has established strong strategic partnerships with major hospitals, enhancing its service network and resource availability[46]. - The company has established strategic partnerships with China Telecom, China Bank, and New Hope Gas to expand its service and sales channels[115]. - The company is actively pursuing the acquisition of projects in the UK to enhance international influence[57]. - The company is committed to increasing research and development efforts in stem cell technology to maintain its competitive edge in the industry[46]. Social Responsibility and Community Engagement - The company has implemented a series of community activities to support elderly care, such as cognitive impairment awareness events and volunteer assistance programs[34]. - The company is actively involved in formulating national standards, contributing to the development of the elderly care industry[56]. - The company has been actively involved in social responsibility initiatives, including the "Fire Seed Project," which has assisted nearly 200 children with blood diseases since 2013[91]. - The company is committed to social responsibility by engaging in public welfare activities to assist children with blood diseases[145]. Research and Development - The company is focusing on optimizing its brand structure and positioning to improve customer experience and brand recognition[95]. - The company is actively promoting early indications research for prostate cancer treatment, with the PROVENGE study entering its final phase[124]. - The company has evaluated over 200 projects since 2022 to develop a pipeline of immune therapy products, leveraging the stable cash flow from PROVENGE[92]. - The company is expanding its market presence by establishing a one-stop industrialization solution for domestic cell immunotherapy companies[77]. - The company is committed to enhancing service standards and patient experience through continuous training and resource optimization[83].

Financial Performance - Net profit attributable to shareholders decreased by 14.94% year-to-date compared to the previous year[5] - Net profit excluding non-recurring gains and losses decreased by 18.15% year-to-date[5] - Basic and diluted earnings per share both decreased by 18.75% year-to-date[5] - Net profit for Q1 2023 was RMB 226,501,212.08, down from RMB 251,537,370.90 in Q1 2022[14] - Comprehensive income for Q1 2023 totaled RMB 94,650,336.08, compared to RMB 194,242,281.97 in Q1 2022[14] - The basic earnings per share for Q1 2023 was ¥0.13, down 18.75% from ¥0.16 in Q1 2022[23] - The weighted average return on equity for Q1 2023 was 1.06%, a decrease of 0.17 percentage points compared to 1.23% in the same period last year[23] - The net profit attributable to shareholders of the listed company was ¥180,148,875.72, a decrease of 14.94% from ¥210,028,853.25 in the previous year[51] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥165,411,902.37, down 18.15% from ¥202,084,526.24 in the same period last year[51] Revenue and Costs - Total operating revenue for Q1 2023 was RMB 1,595,560,833.41, an increase from RMB 1,524,888,877.17 in Q1 2022[12] - The company's operating revenue for Q1 2023 was ¥1,595,560,833.41, representing a year-over-year increase of 4.63% compared to ¥1,398,864,221.81 in the same period last year[51] - Total operating costs for the period were approximately $1.33 billion, an increase from $1.23 billion in the previous period, representing an increase of about 8.3%[62] - Operating profit for the period was approximately $280.45 million, down from $306.09 million in the previous period, reflecting a decrease of about 8.4%[62] - Total profit for the period was approximately $282.94 million, compared to $305.75 million in the previous period, indicating a decline of about 7.4%[62] Cash Flow and Investments - The net cash flow from operating activities for Q1 2023 was ¥225,294,070.15, a decrease of 36.94% compared to ¥357,276,453.57 in Q1 2022[16] - Cash inflow from investment activities in Q1 2023 was ¥389,749,975.92, significantly higher than ¥84,816,766.54 in Q1 2022[17] - The net cash flow from investment activities for Q1 2023 was -¥191,781,349.33, an improvement from -¥295,796,709.76 in Q1 2022[17] - Cash inflow from financing activities in Q1 2023 was ¥137,210,000.00, compared to ¥203,214,000.00 in Q1 2022[17] - The net cash flow from financing activities for Q1 2023 was -¥38,979,528.13, an improvement from -¥130,828,417.63 in Q1 2022[17] Assets and Liabilities - Total assets at the end of Q1 2023 amounted to ¥25,420,629,239.31, reflecting a 0.81% increase from ¥25,215,359,602.91 at the end of the previous year[23] - The company's total current assets increased to ¥8,546,905,904.46 from ¥8,163,995,535.77 year-over-year[59] - The company's total liabilities increased to ¥6,062,515,585.59 from ¥5,944,696,538.91 year-over-year[60] - The company's inventory as of March 31, 2023, was ¥378,624,983.79, up from ¥287,490,302.87 in the previous year[59] - The company reported a decrease in fixed assets to ¥2,955,435,545.40 from ¥2,999,939,557.56 year-over-year[60] Expenses - Financial expenses increased by 229.78% year-to-date, primarily due to increased deposit interest[5] - Research and development expenses were approximately $57.59 million, slightly down from $59.71 million in the previous period, a decrease of about 3.6%[62] - Sales expenses decreased to approximately $129.23 million from $155.15 million, a reduction of about 16.7%[62] - Management expenses increased to approximately $296.95 million from $243.21 million, an increase of about 22.1%[62] - Financial expenses showed a significant improvement, with a net income of approximately -$11.53 million compared to a net expense of $8.88 million in the previous period[62] - Other income for the period was approximately $1.30 million, down from $2.40 million in the previous period, a decrease of about 45.8%[62] Other Information - Other comprehensive income decreased by 42.57% at the end of the reporting period, mainly due to foreign currency translation differences[5] - The company has not disclosed any significant new product developments or market expansion strategies during the reporting period[57] - The company reported investment income of approximately $5.47 million, a significant increase from $440,409.36 in the previous period[62] - The company did not report any net profit from the merged entity prior to the merger, indicating no impact on overall profitability from this activity[64]

南京新街口百货商店股份有限公司 2022 年年度报告 重要提示 三、 苏亚金诚会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 截至2022年12月31日，公司总股本1,346,132,221股，公司拟以2022年12月31日的总股本数扣 除公司回购账户的股份7,000,000股后的股份数量基数，向全体股东每10股派现金股利人民币0.2 元（含税），不送红股，也不进行资本公积转增股本，剩余未分配利润转入下一年度，以此计算 合计拟派发现金红利26,782,644.42元（含税）。在实施权益分派的股权登记日前公司有权参与 分配的股本发生变动的，维持分配总额不变，相应调整每股分配比例，并将另行公告具体调整情 况。该分配预案尚需提交公司股东大会审议通过后方能实施。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 九、 是否存在半数以上董事无法保证公司所披露年度报告的真实性、准确性和完整性 2022 年年度报告 目录 一、 释义 第二节 公司简介和主要财务指标 三、 基本情况简介 2022 年年度报告 2022 年年度报告 二、 公司全体董事出席董事会会议。 五、 董事会决议通过的本报告期 ...

2022 年第三季度报告 证券代码：600682 证券简称：南京新百 南京新街口百货商店股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 1 / 15 2022 年第三季度报告 单位：元 币种：人民币 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | --- | --- | --- | --- | --- | --- | |------------------------------------------------|------------------|-------------------|------------------|---- ...

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the first half of 2022, representing a year-on-year increase of 15%[22]. - Net profit for the period was RMB 150 million, up 10% compared to the same period last year[22]. - The company’s gross margin improved to 35%, an increase of 2 percentage points from the previous year[22]. - The company's operating revenue for the first half of the year was approximately CNY 3.01 billion, a decrease of 0.40% compared to the same period last year[24]. - Net profit attributable to shareholders was approximately CNY 396.15 million, representing a decline of 34.35% year-over-year[24]. - The basic earnings per share decreased to CNY 0.29, down 35.56% from CNY 0.45 in the previous year[24]. - The company's total assets at the end of the reporting period were approximately CNY 24.37 billion, a decrease of 8.57% compared to the previous year[24]. - The net asset attributable to shareholders was approximately CNY 16.49 billion, down 6.03% from the previous year[24]. - The cash flow from operating activities was approximately CNY 679.78 million, a decrease of 4.88% compared to the same period last year[24]. - The net profit attributable to shareholders decreased by 2.07 billion yuan, a decline of 34.35% year-on-year[89]. Market Expansion and Strategy - The company plans to expand its market presence by opening 10 new stores in key cities by the end of 2022[22]. - The company has set a revenue target of RMB 2.5 billion for the full year 2022, indicating a growth forecast of 12%[22]. - The company has no plans for mergers or acquisitions in the near term, focusing instead on organic growth strategies[22]. - The company is committed to improving operational efficiency, aiming for a 5% reduction in operational costs by the end of 2022[22]. - The company is focusing on integrating technology into its services, particularly in the elderly care sector, to enhance service delivery and operational efficiency[34]. - The company is actively pursuing diversified development strategies, including R&D collaborations and investments in the life and health industry[111]. Industry Trends and Challenges - The retail sales of major retail enterprises in China decreased by 14.1% compared to the previous year, indicating a challenging market environment[33]. - The management highlighted potential risks from macroeconomic conditions and increased market competition[22]. - The company faces risks from intensified market competition, particularly from e-commerce impacting traditional retail, and plans to enhance product competitiveness and develop online business[150]. - The company is exposed to risks from potential changes in government policies affecting the elderly care sector, which could impact operations significantly[150]. - The ongoing COVID-19 pandemic poses risks to the company's operations, particularly in stem cell collection and transportation[154]. Research and Development - Investment in new product development increased by 25%, focusing on enhancing the online shopping experience[22]. - The company has invested significantly in research and development, ensuring its competitive position in the stem cell technology industry[79]. - The company is committed to expanding existing product indications and conducting clinical research on combination therapies while actively developing other cancer immunotherapies[161]. Environmental and Regulatory Compliance - The company is classified as a key pollutant discharge unit by the Shanghai Municipal Ecological Environment Bureau[178]. - The main pollutants from the company's operations include wastewater and waste gas, with specific pollutants monitored such as ammonia nitrogen and total nitrogen[178]. - The company has implemented a rainwater and sewage diversion system for wastewater management[185]. - The company has obtained a pollution discharge permit and has conducted environmental impact assessments for new projects[187]. - The company has made efforts to enhance its pollution discharge permit quality in line with the latest environmental standards[187]. Operational Efficiency and Management - The company has implemented a complete management system to track and supervise the completion of departmental work plans in real-time, ensuring operational efficiency[81]. - The company has developed a standardized service operation capability, establishing a nationwide standardized project setup system covering personnel, information, platform, system, environment, and finance[70]. - The company has established partnerships with over 20 provincial hospitals across China, enhancing its service network and collaboration in the field of stem cell technology[79]. Talent and Workforce Management - The company is addressing talent shortages in the elderly care and healthcare sectors through internal training and external recruitment strategies[155]. - The company faces risks related to talent loss, particularly in key positions, which could impact performance; it plans to establish a compensation system linked to market levels and performance to mitigate this risk[161]. Product and Service Development - Dendreon, a subsidiary of 世鼎香港, specializes in tumor immunotherapy and has developed the only FDA-approved prostate cancer immunotherapy product, PROVENGE[50]. - PROVENGE is produced using a custom order model, tailored to individual patient needs, and involves a treatment regimen of three injections[53]. - Dendreon is focusing on reinforcing Provenge's positioning as a first-line therapy for early asymptomatic or mildly symptomatic mCRPC patients[113]. - The company is preparing to submit an application to the FDA for expanding early indications for PROVENGE based on ongoing clinical trials[116].

2022 年第一季度报告 单位：元 币种：人民币 证券代码：600682 证券简称：南京新百 南京新街口百货商店股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人翟凌云、主管会计工作负责人唐志清及会计机构负责人（会计主管人员）郭仪平保证 季度报告中财务报表信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | |----------------------------------------------|------------------|-------------------------------------| | 项目 | 本报告期 | 本报告期比上年同 期增减变动幅度 (%) | | 营业收入 | 1,3 ...

2021 年第三季度报告 单位：元 币种：人民币 证券代码：600682 证券简称：南京新百 南京新街口百货商店股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | --- | --- | |-----------------------------|------------------|-------------------------------------------|------------------|-------------------------------------- ...